Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04629547 · ClinicalTrials.gov registry record · Phase 2
Sleep Trial to Prevent Alzheimer's Disease
A Phase 2 study of Alzheimer Disease and Sleep, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT04629547 is a Phase 2 study of Alzheimer Disease and Sleep that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 200 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04629547, a Phase 2 study of Alzheimer Disease and Sleep, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Suvorexant 20 mg
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04629547
The ClinicalTrials.gov registry entry for NCT04629547 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (93% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04629547 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04629547 about?
NCT04629547 is a clinical study titled "Sleep Trial to Prevent Alzheimer's Disease". The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
What is the current status of trial NCT04629547?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2022-05-25. Estimated completion is 2026-05.
What conditions does trial NCT04629547 study?
This clinical trial studies the following conditions: Alzheimer Disease, Sleep.
What interventions are being tested in trial NCT04629547?
The interventions under investigation include: Placebo (DRUG), Suvorexant 20 mg (DRUG).
Who is sponsoring clinical trial NCT04629547?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04629547 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.